S-1: cbdMD Registers 1.7M Shares for Resale

cbdMD, Inc. filed an S-1 registration statement for the resale of 1.7 million common shares by selling shareholders who acquired Series B Convertible Preferred Stock.

Summary

• A registration statement on Form S-1 has been filed for the potential resale of up to 1,700,000 shares of common stock by Selling Shareholders.
• These shares are issuable upon conversion of Series B Convertible Preferred Stock, which was sold to the Selling Shareholders on September 29, 2025, for aggregate gross proceeds of $1,700,000.
• The company will not receive any proceeds from the sales of common stock by the Selling Shareholders.
• Proceeds from the Series B Preferred Stock issuance are designated for working capital and general corporate purposes.
• The Series B Preferred Stock is convertible at $1.00 per share, subject to a floor conversion price of $0.50 per share, and accrues dividends at a rate of 10% per annum, payable quarterly in shares of common stock or cash.
• Q1 fiscal 2025 marked the first quarter in the company's history as a public company to achieve increased sequential revenues, positive Non-GAAP Net Income (before preferred dividend accrual), and positive EBITDA on a Non-GAAP basis.
• Q3 fiscal 2025 experienced a revenue decline attributed to management's focus on Series A Preferred Stock conversion, weaknesses in the marketing team, and intermittent inventory shortages.
• The company successfully converted all Series A Preferred Stock on May 6, 2025, eliminating $6.7 million in accrued and unpaid dividends, a strategic move to improve stockholders' equity and regain NYSE American listing compliance.
• The company launched 'Oasis,' a hemp-derived THC-infused social seltzer, in Q1 fiscal 2025, a market projected to grow to $4.1 billion by 2028, and has expanded its distribution across several states.

Sentiment

Score: 5

Explanation: The filing presents a balanced view of the company's situation, highlighting recent operational improvements such as positive Non-GAAP earnings and EBITDA in Q1 FY25 and the successful launch of a promising new product line (Oasis). However, these positives are significantly tempered by a revenue decline in Q3 FY25, ongoing NYSE American delisting risk due to insufficient stockholders' equity, substantial dilution from the recent Series B Preferred Stock issuance, and persistent regulatory challenges in the industry. The S-1 itself is a procedural step for a past capital raise, but the underlying business performance and risks are mixed.

Positives

• Achieved positive Non-GAAP Net Income and positive EBITDA in Q1 fiscal 2025, a historical first for the public company.
• Successfully obtained shareholder approval and converted Series A Preferred Stock on May 6, 2025, eliminating $6.7 million in accrued dividends, which is crucial for NYSE American listing compliance.
• Launched 'Oasis' hemp-derived THC-infused seltzer in Q1 fiscal 2025, entering a rapidly growing market segment projected to reach $4.1 billion by 2028.
• The Oasis brand earned multiple medals at the prestigious LA Spirits Awards in April 2025, indicating strong product acceptance and brand potential.
• Expanded Oasis distribution across Alabama, Georgia, North Carolina, parts of South Carolina, the Florida Panhandle, Tennessee, and Minnesota, with further growth anticipated in fiscal 2026.
• Rebuilt the marketing team and improved customer acquisition funnels in Q3 fiscal 2025, resulting in a growing new customer base in July and key direct-to-consumer metrics trending positively.
• Increased inventory investments to correct prior shortages and ensure better product availability.

Negatives

• Experienced a revenue decline during the third fiscal quarter of 2025.
• Management attention was temporarily diverted from core business operations due to the process of securing shareholder approval for Series A Preferred Stock conversion.
• Identified and addressed weaknesses within the marketing team, leading to leadership changes late in Q2 fiscal 2025.
• Conservative cash management in Q2 fiscal 2025 led to inventory levels dropping below optimal thresholds, coupled with delays in product testing, resulting in intermittent stock shortages across several SKUs.
• Faced a notable uptick in both state and federal regulatory activity in fiscal 2025, introducing new labeling requirements and proposals that could limit consumer choice and significantly impact market access, requiring increased resources for compliance and lobbying.
• Received notification from the NYSE American on December 31, 2024, for non-compliance with continued listing standards, specifically Section 1003(a)(i) due to stockholders' equity of $1.9 million as of September 30, 2024, below the $2.0 million threshold.
• Remains subject to a prior NYSE American non-compliance notification from June 5, 2024, and a compliance plan accepted on August 20, 2024, for stockholders' equity under $4.0 million (Section 1003(a)(ii)).

Risks

• Failure to satisfy NYSE American continued listing standards could result in delisting of securities, leading to a lack of trading market, reduced liquidity, decreased analyst coverage, and an inability to obtain additional financing.
• The company is currently not in compliance with NYSE American listing standards regarding stockholders' equity, with $1.9 million as of September 30, 2024, falling below the required $2.0 million and $4.0 million thresholds.
• Increased state and federal regulatory pressure in the hemp and cannabinoid wellness category may persist, potentially limiting consumer choice, significantly impacting market access, and requiring continued strategic investment.
• Proceeds from the Series B Preferred Stock may be used in ways that do not yield a significant return or enhance the value of common stock.
• The issuance of shares upon conversion of the Series B Preferred Stock, as well as the exercise of outstanding options, restricted stock awards, and warrants, will cause immediate and substantial dilution to existing shareholders.

Future Outlook

Management is focused on achieving positive earnings by optimizing the product portfolio, right-sizing the cost structure, and investing in marketing efforts that yield a positive return on customer acquisition. The company anticipates continued regulatory pressure in the hemp and cannabinoid wellness category, necessitating ongoing strategic investment to protect market access and consumer choice. Growing revenue from new Oasis distribution markets is expected in fiscal 2026, capitalizing on the projected growth of the hemp-derived THC beverage market to $4.1 billion by 2028.

Management Comments

• "Management continues to be very focused on our goal of delivering positive earnings through a combination of optimizing our product portfolio, right-sizing our cost structure and investing in marketing that will provide positive return on customer acquisition."
• "Our top priority for the quarter was securing shareholder approval to amend our articles of incorporation and convert the Series A Convertible Preferred Stock... This strategic move was essential to improving stockholders equity, and our plan to regain compliance with NYSE American continued listing standards and preserve our Common Stock listing on the NYSE American."
• "We remain focused on growing the Company in a smart, profitable manner along with appropriate cost controls."

Industry Context

The company operates within the evolving CBD, functional mushroom, and hemp-derived THC beverage markets. The hemp-derived THC beverage segment is highlighted as a rapidly expanding area, with sales more than doubling in 2024 and projected to reach $4.1 billion by 2028. However, the broader hemp and cannabinoid wellness category faces increasing state and federal regulatory scrutiny, which could limit consumer choice and market access, requiring significant industry resources for compliance and lobbying efforts.

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders:** Existing common shareholders will experience dilution from the potential conversion of 1,700,000 Series B Preferred Stock shares and the exercise of outstanding options and warrants. However, the conversion of Series A Preferred Stock and elimination of $6.7 million in accrued dividends is positive for improving stockholders' equity and maintaining NYSE American listing.
• **Selling Shareholders:** Will receive proceeds from the resale of their common stock, but the company will not. They are subject to beneficial ownership limitations and have agreed not to engage in short selling or hedging.
• **Customers:** May face intermittent product availability issues due to past inventory shortages and delays from new labeling requirements. The launch of the Oasis THC-infused seltzer expands product offerings.
• **Employees:** The marketing team underwent leadership changes to improve performance.
• **Creditors:** The Series B Preferred Stock ranks senior to all other capital stock in liquidation, which could affect the recovery prospects of other creditors in a dissolution scenario.

Next Steps

• Selling Shareholders may offer and sell their registered common stock from time to time.
• The company will continue efforts to regain and maintain compliance with NYSE American listing standards, with a deadline of December 5, 2025, for its current compliance plan.
• Management plans to continue optimizing the product portfolio, right-sizing the cost structure, and investing in marketing to drive positive customer acquisition returns.
• The company expects to continue strategic investment in regulatory engagement to protect market access and consumer choice in the face of ongoing regulatory pressure.
• Anticipate growing revenue from new Oasis distribution markets in fiscal 2026.

Key Dates

Recommendation

The company exhibits a mixed financial and operational landscape. While Q1 fiscal 2025 showed promising signs of profitability and the launch of the Oasis THC beverage line taps into a high-growth market, significant challenges persist. The revenue decline in Q3 fiscal 2025, ongoing non-compliance with NYSE American listing standards, and the substantial dilution from the Series B Preferred Stock conversion create considerable uncertainty. Furthermore, the increasing regulatory pressure in the hemp and cannabinoid wellness industry adds another layer of risk. Given these balanced factors, a 'Hold' recommendation is appropriate, allowing investors to monitor the company's ability to sustain its operational improvements, resolve its listing issues, and effectively navigate the complex regulatory environment before making further investment decisions.

Keywords

CBD, cannabidiol, hemp, Series B Preferred Stock, S-1, registration statement, NYSE American, YCBD, YCBD stock, YCBD shares, YCBD preferred stock, cbdMD, Paw CBD, ATRx Labs, Herbal Oasis, THC beverages, functional mushrooms, regulatory risk, dilution, capital raise